CAR-T cell therapy for tough-to-treat membranous nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether specially engineered immune cells (CAR-T cells) can help people with a kidney condition called primary membranous nephropathy that has not improved with standard treatments. The goal is to see if this therapy can reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary membranous nephropathy confirmed by kidney biopsy.
- Your kidney disease is considered moderate- or high-risk and has not responded well to at least 6 months of standard therapy (steroids, cyclophosphamide, or rituximab).
- You are 18 years or older.
- Your kidney function (eGFR) is at least 30, and your other organs (liver, heart, lungs) are working well enough.
- You do not have a secondary cause for your kidney disease (like lupus, cancer, or certain infections).
- You have not had certain cell therapies before, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental cell therapy (CAR-γδ T cells) for people with certain autoimmune kidney diseases that have not responded to usual treatments. The goal is to see if this therapy is safe and can help control the disease.
This trial is testing a new kind of immune therapy, called UCAR-T, which uses reprogrammed white blood cells to help treat a severe type of kidney disease (membranous nephropathy) that has not improved with standard medicines. The goal is to see if this therapy can calm the immune attack on the kidneys and reduce protein loss in urine.
This trial tests a new CAR-T cell treatment for children and adults with steroid-resistant nephrotic syndrome (SRNS), a kidney condition that doesn't get better with standard medicines. The goal is to see if this therapy can help improve kidney function when other treatments have failed.
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
Hear when a new Refractory Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.